Note: Ingredients listed on restricted chemical lists
EC/CAS
231-633-2/7664-38-2
Name of the chemical
phosphoric acid
Concentration
1-5
General Information
Version
4.0
Revision date
2022-12-20
Product name
Bis-Silane Part B
1.2.1 Relevant identified uses
For Rx only
Manufacturer Name
EC REP
Emergency telephone
1-800-424-9300, 1-703-527-3887
Icons in SDS
Company Information
company name
BISCO, Inc
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H225
Hazard statements
Code
Statements
H225
Highly Flammable liquid and vapour
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Highly flammable liquid and vapour. May cause respiratory irritation. Causes skin irritation. Causes serious eye irritation.
2.2 Label elements
Labelling
Hazard pictograms
GHS02
Signal word
Danger
Hazard statements
H225 - Highly flammable liquid and vapour.
Precautionary statements
P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P233 - Keep container tightly closed. P241 - Use explosion-proof electrical/ventilating equipment. P280 - Wear protective gloves/protective clothing/eye protection. P303+P361+P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water or shower. P370+P378 - In case of fire: Use media other than water to extinguish. P403+P235 - Store in a well-ventilated place. Keep cool. P501 - Dispose of contents/container to hazardous or special waste collection point in accordance with local/regional/national.
2.3 Other hazards
Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component Phosphoric Acid, conc=85% (7664-38-2) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %